The Optimization of Mycoplasm Pneumonia Antibiotic Therapy

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Mycoplasma pneumoniae, an important pathogen of community acquired pneumonia,are becoming more and more resistant to macrolide. The study aim is to optimize anti-infection therapy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Capital Medical University
• Treatments: Anti-Bacterial Agents; Antibiotics, Antitubercular; Azithromycin; Cephalosporins; Moxifloxacin; Norgestimate, ethinyl estradiol drug combination

Criteria

Inclusion Criteria:

1. Confirmed community acquired pneumonia

2. 60ys≥age≥18 ys

3. Respiratory symptom (cough accompanied by little or no sputum)

4. New infiltration showed by chest radiology(x-ray or CT)

5. Lung signs was not obvious

6. White blood cell<10,000/mm3

7. Without underlying diseases or mild

Exclusion Criteria:

1. Age<18ys or >60ys

2. Pregnancy or breast-feeding

3. Over one week after the onset of symptoms

4. HIV infection

5. Recent 90-day hospitalized history(length of stay greater than 2 days)

6. Live in nursing homes or rehabilitation hospitals

7. Taken macrolides or quinolones medicines before enrollment